

Syncona Update

June 2020



Syncona

Building the next generation of healthcare companies

Key Announcements

[Kemal Malik Appointed as Non-Executive Director](#)

15.06.2020

Announced the appointment of Dr Kemal Malik as a Non-Executive Director with immediate effect. Kemal has 30 years of experience in global pharmaceutical research and development and has been responsible for bringing many innovative medicines to commercialisation.

Kemal has spent much of his recent career at Bayer where, for the last six years, he served on the Board of Management leading innovation across the group. He was also responsible for Bayer LEAPS during this time, an organisational unit for strategic venturing in areas of disruptive innovation (cell and gene therapy). For the ten years prior to this, Kemal was Head of Global Development and Chief Medical Officer at Bayer Healthcare. His early career began with roles in medical affairs, clinical development and new product commercialisation at Bristol-Myers Squibb.

[Syncona FY20: Martin Murphy discusses the outlook for Syncona](#)

11.06.2020

Watch the full video on our website above.

[Syncona FY20: Martin Murphy discusses the impact of COVID-19](#)

11.06.2020

Watch the full video on our website using the link above.

[Syncona FY20: Martin Murphy discusses FY20 results](#)

11.06.2020

Watch the full video on our website using the link above.

[Syncona Full Year Results Presentation](#)

11.06.2020

Link to presentation above.

[Syncona Full Year Results RNS](#)

11.06.2020

Syncona made good progress against its strategic goals in 2020. We deployed £206.4 million of capital into our life science companies as they generated positive clinical data and added a new company to the portfolio. We successfully sold two companies, significantly strengthening our strategic capital pool, and expanded our expert team. Our companies remain strongly positioned to deliver value over the long term and our vision to deliver transformational treatments for patients remains as important as ever.

Key Media Coverage

[Syncona: a biotech trust that's going for a song](#)

MoneyWeek 15.06.2020

Max King provides an overview of Syncona and its portfolio in a feature by MoneyWeek. After highlighting what to watch out for within the portfolio, Max suggests that Syncona's price significantly undervalues its potential and notes that there is plenty of scope for strong returns in future. Within the piece, Syncona CIO Chris Hollowood explains that there has been a revolution in biotechnology and that

it no longer costs \$1bn to develop a drug. “Precision medicine, reliant on human genetics, enables faster development, smaller, more capital-efficient clinical trials and a targeted commercial roll-out,” Chris explains.

[Syncona a value falls after sell-off hits investments](#)

The Times 12.06.2020

Alex Ralph of The Times covered Syncona’s full year results, noting the decline in net asset value and the strategic progress that the company made throughout the year. Alex highlighted the impact of the two company divestments that completed during the year and how they enabled Syncona to make long-term funding commitments and to deploy £206.4 million into its portfolio of next-generation companies.

Achilles Therapeutics

Developing novel cancer immunotherapies targeting clonal neoantigens

Key Announcements

[Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small lung cancer](#)

23.06.2020

Achilles announced the first patient has been dosed in its Phase I/II CHIRON study of a clonal neoantigen T cell (cNeT) therapy in patients with advanced non-small cell lung cancer (NSCLC). The precision infiltrating lymphocyte (TIL) therapy uses cutting edge genomics to selectively target patient specific clonal neoantigens – targets which are believed to be present on all tumour cells.

[Achilles – Jefferies Healthcare Conference Presentation](#)

02.06.2020

Link to presentation above.

Key Media Coverage

[Bringing precision to solid tumor targets](#)

InVivo 10.06.2020

Ben Comer interviews Iraj Ali, the Chief Executive of Achilles Therapeutics and discusses why the company believes that its clonal neoantigen-targeting T cell (cNeT) products, combined with an industrial scale advanced manufacturing capability and predictive bioinformatics platform, will have a transformational impact on patients with solid tumours and metastasized cancer.

Autolus

Developing next generation programmed T cell therapies for the treatment of cancer

Key Announcements

[Autolus AACR Data Update Presentation](#)

25.06.2020

Link to presentation above.

[New data presented during Virtual 2020 AACR Annual Meeting](#)

22.06.2020

Conference call and webcasts were held on June 25th. Preclinical data related to AUTO5 and AUTO6NG were announced, with an oral presentation related to AUTO7 at the American Association for Cancer Research.

[Autolus presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress](#)

12.06.2020

New data announced highlighting progress on AUTO1 program at the European Hematology Association EHA25 Virtual Congress. *"Approximately 60% of adult ALL patients relapse or are refractory to first line therapy and there continues to exist a high unmet need," said Dr. Michael Bishop, MD, Professor of Medicine and Director of the Cellular Therapy Program at University of Chicago Medicine. "AUTO1 is a novel CD19 CAR T candidate with a compelling activity and safety profile and has the potential to change standard of care as a curative therapy for r/r ALL."*

Dr Wendy Osbourne presented Alexander Phase 1/2 clinical trial data for AUTO3 for DLBCL. As follows is a link to a video where she summarises the data: [\(click here\)](#).

[Autolus EHA Data Update Presentation](#)

12.06.2020

Link to presentation above.

[Autolus Corporate Presentation](#)

02.06.2020

Link to presentation above.

[AUTO3 Data Update – ASCO Presentation](#)

01.06.2020

Link to presentation above. Please note the AUTO3 DLBCL press release summary was provided in last month's update.

Quell Therapeutics

Developing engineered T regulatory (T-reg) cell therapies

Key Announcements

[Quell strengthens its Board with appointments of Dr Dhaval Patel and Sir Robert Lecher, and hires Natalie Belmonte as SVP Research & Translation](#)

11.06.2020

Dhaval Patel is an Executive Vice President and Chief Scientific Officer of UCB where he is a member of the UCB Executive Committee and leads the Company's research organisation. He joined UCB from Novartis, where, over a period of 11 years he led various biomedical research teams in areas of neurology, autoimmunity, transplantation, and inflammation. In 2010, he became the Head of Research for the Novartis Institutes for BioMedical Research (NIBR) Europe.

Professor Sir Robert Lechler is currently Provost and Senior Vice-President (Health) at King's College London, Executive Director of King's Health Partners and President of the Academy of Medical Sciences. In 2012 Robert was awarded a Knighthood for Services to Academic Medicine and in 2015 was elected as the President of the UK Academy of Medical Sciences.

Dr Natalie Belmonte has over 15 years of experience working in the field of cell therapy in both academic and biotech environment and has extensive experience with the development of Treg cell and Mesenchymal Stem Cell based therapies. Before joining Quell Therapeutics, Nathalie served as Chief Operating Officer at Promethera Biosciences. Prior to that, she served as VP R&D at TxCell developing Treg cell-based therapy for autoimmune and inflammatory diseases.

SwanBio Therapeutics

Developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of neurological diseases

Key Announcements

[Appointment of Steven Zelenkofske, DO, as CMO](#)

01.06.2020

SwanBio announced the appointment of Steven Zelenkofske as Chief Medical Officer. Dr. Zelenkofske brings more than 20 years' experience to the SwanBio team. Most recently serving as CMO at Achillion Pharmaceuticals, a clinical stage company focused on complement inhibitors, and at UniQure, a clinical stage gene therapy company focused on genetic diseases. Dr. Zelenkofske has been responsible for multiple NDA filings and approvals throughout his career. He has held leadership positions at Regado Biosciences, Astrazeneca, Sanofi-Aventis, Boston Scientific and Novartis. His work has spanned numerous therapeutic areas including neurology, immunology, hematology, cardiovascular, metabolic diseases, diabetes, and nephrology.